This finding not only offers a mechanistic insight to DPP-4i-driven BC metastasis by ROS-NRF2 activation, but also provides new avenues to eliminate the “dark side” of NRF2 by targeting HO-1. This evidence concerns the gene HMOX1 and breast cancer.